Literature DB >> 18273537

Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury.

X Antón Alvarez1, Carolina Sampedro, Jesús Figueroa, Iván Tellado, Andrés González, Manuel García-Fantini, Ramón Cacabelos, Dafin Muresanu, Herbert Moessler.   

Abstract

Changes in quantitative EEG (qEEG) recordings over a 1-year period and the effects of Cerebrolysin (Cere) on qEEG slowing and cognitive performance were investigated in postacute moderate-severe traumatic brain injury (TBI) patients. Time-related changes in qEEG activity frequency bands (increases of alpha and beta, and reductions of theta and delta relative power) and in qEEG slowing (reduction of EEG power ratio) were statistically significant in patients with a disease progress of less than 2 years at baseline, but not in those patients having a longer disease progress time. Slowing of qEEG activity was also found to be significantly reduced in TBI patients after 1 month of treatment with Cere and 3 months later. Therefore, Cere seems to accelerate the time-related reduction of qEEG slowing occurring in untreated patients. The decrease of qEEG slowing induced by Cere correlated with the improvement of attention and working memory. Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273537     DOI: 10.1007/s00702-008-0024-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  53 in total

1.  An EEG severity index of traumatic brain injury.

Authors:  R W Thatcher; D M North; R T Curtin; R A Walker; C J Biver; J F Gomez; A M Salazar
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

2.  Performance characteristics of postacute traumatic brain injury patients on the WAIS-III and WMS-III.

Authors:  B N Axelrod; N L Fichtenberg; P C Liethen; M A Czarnota; K Stucky
Journal:  Clin Neuropsychol       Date:  2001-12       Impact factor: 3.535

3.  Effects of head and extracranial injuries on serum protein S100B levels in trauma patients.

Authors:  Olli Savola; Juhani Pyhtinen; Tuomo K Leino; Simo Siitonen; Onni Niemelä; Matti Hillbom
Journal:  J Trauma       Date:  2004-06

4.  Sleep organization pattern as a prognostic marker at the subacute stage of post-traumatic coma.

Authors:  M Valente; F Placidi; A J Oliveira; A Bigagli; I Morghen; R Proietti; G L Gigli
Journal:  Clin Neurophysiol       Date:  2002-11       Impact factor: 3.708

5.  IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function.

Authors:  E Csuka; M C Morganti-Kossmann; P M Lenzlinger; H Joller; O Trentz; T Kossmann
Journal:  J Neuroimmunol       Date:  1999-11-15       Impact factor: 3.478

6.  A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

Authors:  X A Alvarez; R Cacabelos; M Laredo; V Couceiro; C Sampedro; M Varela; L Corzo; L Fernandez-Novoa; M Vargas; M Aleixandre; C Linares; E Granizo; D Muresanu; H Moessler
Journal:  Eur J Neurol       Date:  2006-01       Impact factor: 6.089

7.  Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury.

Authors:  M R Emmerling; M C Morganti-Kossmann; T Kossmann; P F Stahel; M D Watson; L M Evans; P D Mehta; K Spiegel; Y M Kuo; A E Roher; C A Raby
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

8.  Peak alpha frequency: an electroencephalographic measure of cognitive preparedness.

Authors:  Efthymios Angelakis; Joel F Lubar; Stamatina Stathopoulou; John Kounios
Journal:  Clin Neurophysiol       Date:  2004-04       Impact factor: 3.708

9.  Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors.

Authors:  R Cacabelos; J Caamaño; M J Gómez; L Fernández-Novoa; A Franco-Maside; X A Alvarez
Journal:  Ann N Y Acad Sci       Date:  1996-01-17       Impact factor: 5.691

10.  Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

Authors:  M Panisset; S Gauthier; H Moessler; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2002-07       Impact factor: 3.575

View more
  4 in total

Review 1.  A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.

Authors:  Iman El Sayed; Adel Zaki; Akram M Fayed; Gihan M Shehata; Sherif Abdelmonem
Journal:  Neurosurg Rev       Date:  2016-08-18       Impact factor: 3.042

2.  Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.

Authors:  Edward Rockenstein; Kiren Ubhi; Emiley Pham; Sarah Michael; Edith Doppler; Philipp Novak; Chandra Inglis; Michael Mante; Anthony Adame; X Anton Alvarez; Herbert Moessler; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2011-07-25       Impact factor: 4.164

3.  Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis.

Authors:  Fariborz Ghaffarpasand; Saeed Torabi; Ali Rasti; Mohammad Hadi Niakan; Sara Aghabaklou; Fatemeh Pakzad; Maryam Sadat Beheshtian; Reza Tabrizi
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-27       Impact factor: 2.570

Review 4.  Making Waves in the Brain: What Are Oscillations, and Why Modulating Them Makes Sense for Brain Injury.

Authors:  Aleksandr Pevzner; Ali Izadi; Darrin J Lee; Kiarash Shahlaie; Gene G Gurkoff
Journal:  Front Syst Neurosci       Date:  2016-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.